MAPT and Alzheimer disease: Transgenic C. elegans that expressed human Aβ1‐42 or Tau have been constructed and used for screening anti‐AD drug, identifying the underlying molecular mechanism of the compounds and revealing the pathogenesis of AD.8, 9, 10